In this sense, poly [ADP ribose] polymerase (PARP), delta-like canonical Notch ligand 3 (DLL3) in SCLC-A subtypes and Aurora kinase in SCLC-A constitute promising drug targets [30,31]. The gene discussed is DLL3; the disease is small cell lung carcinoma.